4-methyl-indan-1,2-dione-2-oxime

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 4-methyl-indan-1,2-dione-2-oxime
• 英文别名: Indanone, 2-hydroxyimino-4-methyl-；(2E)-2-hydroxyimino-4-methyl-3H-inden-1-one
• 化学式: C₁₀H₉NO₂
• 分子量: 175.187
• InChiKey: FQPVPHWXPVOJQA-PKNBQFBNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS
  申请人：Chow Ken

  公开号：US20080255239A1

  公开（公告）日：2008-10-16

  Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

  本文揭示了治疗化合物、方法、组合物和相关药物。
• 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE
  申请人：INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)

  公开号：US20150099732A1

  公开（公告）日：2015-04-09

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.

  本发明通常涉及治疗化合物领域。更具体地，本发明涉及某些3-芳基-5-取代-2H-异喹啉-1-酮化合物，该化合物在抑制PARP（例如PARP1，TNKS1，TNKS2等）和/或Wnt信号传导方面具有作用。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物，在体内和体外，来抑制PARP（例如PARP1，TNKS1，TNKS2等）；抑制Wnt信号传导；治疗通过抑制PARP（例如PARP1，TNKS1，TNKS2等）改善的疾病；治疗通过抑制Wnt信号传导改善的疾病；治疗癌症等增生症状。
• Isoquinoline aminopyrazole derivatives
  申请人：Chen Li

  公开号：US20070179151A1

  公开（公告）日：2007-08-02

  The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

  本发明涉及式I的化合物：其药学上可接受的盐或酯，对映体形式，非对映异构体和外消旋体，以及制备这些化合物，含有它们的制药组合物和其制造，以及在控制或预防癌症等疾病中使用这些化合物的用途。
• ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1966190A1

  公开（公告）日：2008-09-10
• US7572809B2
  申请人：——

  公开号：US7572809B2

  公开（公告）日：2009-08-11